Hydrogels, bioplastics, and techniques for generating the same are described herein. An example method includes generating a resin including a globular protein, a co-monomer, water, and a photoinitiator. A hydrogel is generated by exposing the resin to light, thereby polymerizing the globular protein and the co-monomer. Further, the example method includes dehydrating the hydrogel by removing at least a portion of the water; and rehydrating the hydrogel in the presence of a hydrogen bonding agent.

The absorbent article of the invention has a liquid impervious backsheet and a liquid pervious topsheet joined to the backsheet. The topsheet has an inner surface oriented toward the interior of the absorbent article and an outer surface oriented toward the skin and hair of the wearer when the absorbent article is being worn and an absorbent core positioned between the topsheet and the backsheet. At least a portion of the topsheet outer surface comprises an effective amount of a lotion coating which is semi-solid or solid at 20 degrees C., the lotion coating comprising: (i) from about 10 to about 95% of a substantially water free emollient having a plastic or fluid consistency at 20 degrees C. wherein the emollient contains 5% or less water, the emollient comprising a member selected from the group consisting of petroleum-based emollients, fatty acid ester emollients, alkyl ethoxylate emollients, and mixtures thereof; (ii) from about 5 to about 90% of an agent capable of immobilizing the emollient on the outer surface of the topsheet, the immobilizing agent being miscible with the emollient, the immobilizing agent having a melting point of at least about 35 degrees C. wherein the immobilizing agent is selected from the group consisting of polyhydroxy fatty acid esters, polyhydroxy fatty acid amides, C14-C22 fatty alcohols, C14-C22 fatty acids, C14-C22 fatty alcohol ethoxylates with a degree of ethoxylation of 4 or less, and mixtures thereof.

The present disclosure is directed to a class of fluorinated copolymers, such as a PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline.

The present disclosure relates to methods of treating or preventing a biofilm-related infection and methods of preventing and treating biofilm formation on indwelling medical devices, implants, and non-medical surfaces comprising administering at least one soluble microbial protein that is encoded by an exopolysaccharide biosynthetic operon or functional gene cluster, wherein the protein comprises a glycosyl hydrolase domain. The present disclosure further provides particular soluble glycosyl hydrolases and compositions thereof.

Antimicrobial micro- or nanoparticles comprising a chlorhexidine salt and an anion, and a method of making the antimicrobial micro- or nanoparticle, are disclosed. The anion in the salt is selected form oxoanions and partially hydrogenated oxoanions of phosphorus, carbon, nitrogen, and sulfur.

Medical articles formed from a polyurethane-based resin including an ionically-charged modifier provide enhanced properties. The polyurethane-based resin is a reaction product of ingredients comprising: a diisocyanate; a diol chain extender; a polyglycol; and an ionically-charged modifier incorporated into a backbone, as a side chain, or both of the polyurethane-based resin. Embodiments include the ionically-charged modifier is a combination of anionic and cationic modifiers. Embodiments include the ionically-charged modifier is zwitterionic. Medical articles herein either have inherent antimicrobial and/or anti-fouling characteristics or can easily bond ionic active agents to provide desirable material properties, including antimicrobial, anti-fouling, and/or radiopacity.

A medical product comprises a biodegradable filament and a non-biodegradeable coating. The biodegradable filament forms a stent body having a first end portion, a middle portion, and a second end portion opposite the first end portion. The middle portion extends between the first and second end portions. The non-biodegradeable coating encapsulates the at least one biodegradable filament along the middle portion of the stent body. The non-biodegradeable coating forms a barrier such that the non-biodegradeable coating prevents degradation of the at least one biodegradable filament along the middle portion. The first and second end portions are uncoated. After implantation, the end portions of the stent may biodegrade. The middle portion will not biodegrade due to its encapsulation by the non-biodegradeable coating.

A chest drainage system including a collection device configured to receive fluid from the pleural cavity of a patient. A sensor is included to detect a pressure differential in the fluid. A display is configured to display a trend in occurrences of changes in pressure of the fluid over time in predetermined time increments based on a number of detections of pressure differentials that exceed a predetermined pressure differential during each of the predetermined time increments. The trend is correlative to the percentage of time that the patient is deemed to have an air leak in the pleural cavity in the predetermined time increments. The trend is derived from a ratio of the quantity of respiratory cycles of the patient for which the predetermined pressure differential is detected (QRC.sub.leak) in the predetermined time increments to the total quantity of respiratory cycles of the patient in respective predetermined time increments (QRC.sub.total).

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.

Systems, methods, and apparatuses for increasing liquid absorption are described. Some embodiments may include a dressing having an absorbent layer containing super-absorbent material as well as ionic-exchange media (IEM). In some embodiments, the absorbent layer may include absorbent fibers. The absorbent fibers may each include a super-absorbent core surrounded by a water-permeable layer onto which ionic-exchange media (IEM) may be grafted. As liquid comes into contact with the IEM, its ionic nature may be reduced, therefore protecting the absorbent qualities of the super-absorbent material.